Risk of tumorigenicity in mesenchymal stromal cell-based therapies-Bridging scientific observations and regulatory viewpoints

L Barkholt, E Flory, V Jekerle, S Lucas-Samuel, P Ahnert, L Bisset, D Buscher, W Fibbe, A Foussat, M Kwa, O Lantz, R Maciulaitis, T Palomaki, C K Schneider, L Sensebe, G Tachdjian, K Tarte, L Tosca, P Salmikangas